Articles tagged with Vaccine Development
Researchers at Houston Methodist are working on a national consortium to develop vaccines against two common and destructive strains of herpesviruses. The project aims to create prophylactic and therapeutic vaccines using a computational toolkit that could transform vaccine development.
Researchers at Karolinska Institutet have identified a new potential risk marker for cardiovascular disease in older women. Low levels of an anti-inflammatory antibody are associated with a higher risk of heart attack and coronary heart disease, independent of other known risk factors.
Researchers at La Jolla Institute for Immunology have developed six lines of humanized mice to study human cases of COVID-19, shedding light on SARS-CoV-2's movement through the body and varying symptoms. The models help understand how different genetic backgrounds influence disease progression.
Researchers have developed an antibody that can identify Campylobacter jejuni and inhibit its growth, reducing pathogenicity. The antibody targets a multiprotein complex essential for the bacteria's energy production, making it a potential target for therapy and vaccination.
Researchers at MIT found that a two-dose schedule for an HIV vaccine can generate a strong response to the virus, outperforming a traditional seven-dose regimen. The first dose primes the immune system, helping it to produce antibodies more effectively when a larger dose is administered one week later.
Researchers at La Jolla Institute for Immunology have captured the first detailed images of the Ebola virus nucleocapsid structure, which is crucial for replicating in host cells. This breakthrough may accelerate the development of universal antivirals that target this viral structure to combat multiple filoviruses.
Vanderbilt University Medical Center has joined ReVAMPP, a $100 million program to develop vaccines and antibody therapies against emerging viral threats. The center will focus on nine virus groups that pose the greatest risk to human health, including bunyaviruses and picornaviruses.
Scientists at WashU Medicine are developing strategies and tools to produce vaccines and antibody-based therapies for viruses from five understudied families. The effort aims to rapidly respond to potential future pandemics, with funding totaling $90M over three years.
The development of vaccine adjuvants has evolved significantly, shifting from empirical methods to a more structured approach grounded in rational drug design. This new era emphasizes the importance of understanding structural and functional traits of adjuvants.
Researchers from Thomas Jefferson University and the University of Maryland Baltimore developed a promising new vaccine candidate that protects against Lassa fever. The study demonstrated the vaccine effectively prevents severe cases of the disease and death in preclinical animal models, paving the way for research in people.
A new study published in Microorganisms highlights the importance of small molecule drugs that target the unchanging parts of the SARS-CoV-2 virus. The research suggests that these stable targets could provide a consistent and reliable treatment option for COVID-19, even as vaccines are updated to address changing viral strains.
Researchers at the University of Copenhagen have identified the protein complex that enables the hepatitis C virus to infect cells. This discovery is a significant step towards developing a vaccine against the disease, which causes chronic inflammation and 300,000 deaths annually worldwide. The study's results, published in Nature maga...
A new framework from a global team of scientists aims to overcome translational hurdles in nanomedicine development. The DELIVER guidelines provide early-stage recommendations for maximizing clinical translation and enabling the successful development of new nanomedicine treatments.
Researchers developed a monoclonal antibody called SC27 that targets multiple parts of the SARS-CoV-2 spike protein, including conserved sections. The antibody shows promise against various COVID-19 variants and related coronaviruses, potentially benefiting immunocompromised patients
Researchers developed artificial lymphoid organ-chips to recreate human immune system's response to booster vaccines. The technology could potentially be used to evaluate the likely effectiveness of new protein and mRNA-based booster vaccines for COVID-19 and other infectious diseases.
A team of researchers from Osaka University has pinpointed the B cells responsible for boosting COVID-19 immunity after vaccination. They found that activated atypical B cells are the main responders to mRNA vaccines, providing a new way to assess vaccine response and underlying biology.
A global therapeutics development coalition is proposed to invigorate the pipeline and drive advocacy for increased investment. The coalition aims to develop two Phase-2 ready therapeutics for virus families of pandemic potential, with a focus on equitable access.
A subset of CD4 T cells create an anti-inflammatory environment within the lung tissue, protecting against TB reinfection by limiting bacterial growth and disease severity. The discovery complements previous research on protective immune T cells in controlling TB infection, suggesting a potential key to improving existing vaccines.
Researchers in China used a scenario experiment to test messaging strategies on COVID-19 vaccine uptake. The study found that emphasizing personal risk rather than personal gain or community benefits was most effective in persuading people to get vaccinated.
A new universal flu vaccine candidate has shown strong immune response and protection against severe infection in mice. The vaccine, developed using the COBRA methodology, targets multiple strains of influenza viruses, including H1N1, H3N2, and H5N1, which pose a high risk to humans.
The field of cancer immunotherapy is advancing with innovations in precision medicine, including adoptive cell transfer therapy, TCR-engineered T cells, and natural killer cell therapy. Therapeutic vaccines are also being developed to target specific cancer antigens, offering new treatment options for patients.
A new HPV vaccine has been developed that protects against all cancer-causing HPV types and triggers cellular immune responses to eliminate infected cells. The vaccine's thermal stability and affordability make it an ideal solution for increasing vaccination rates in developing countries.
A recent study has confirmed the efficacy and safety of the dengue vaccine TAK-003, which reduces the risk of contracting the disease by over 50%. The vaccine has shown a high safety profile, with more than 90% of adults and children developing antibodies after administration.
A Phase 1 study evaluates an individualized neoantigen therapy, showing it is well-tolerated and boosts immune activity against cancer-causing cells. The therapy induces multiple forms of T cell proliferation and sustained responses in patients with melanoma and lung cancer.
Researchers from POSTECH and KRICT created a 3D artificial lung using bioprinting technology, closely mimicking the human respiratory tract. This model allows for accurate testing of COVID-19 drugs and development of therapeutic treatments, potentially shortening the drug development process to under 5 years.
Researchers at Stanford University developed a nanoparticle platform to make vaccines more effective against various pathogens. The platform allows for the elicitation of different immune responses, enabling the identification of the most effective type of protection.
Researchers at the University of Houston have developed two nasal sprays, NanoSTING and NanoSTING-SN, to prevent respiratory virus transmission. NanoSTING is an immune activator that can protect against multiple viruses, while NanoSTING-SN is a pan-coronavirus vaccine that can prevent transmission to unvaccinated individuals.
A team of researchers from the University of York and Hull York Medical School has developed a new, safe and effective way to infect volunteers with the parasite that causes leishmaniasis, allowing for the testing of vaccines and preventative measures.
Researchers at WashU Medicine developed a nasal COVID-19 vaccine that halted transmission in hamsters, showing promise for controlling respiratory infections. The vaccine targeted the virus's entry points in the nose and mouth, reducing viral replication and preventing spread.
Researchers at La Jolla Institute for Immunology have discovered immune cells, such as tissue resident memory cells, in the upper airway that can fight infections and build long-term immunity. These findings may lead to better vaccines and a deeper understanding of immunity against respiratory pathogens.
A University of Vienna research team has developed a new generation of RNA building blocks for high-density microarrays, significantly reducing production time. This breakthrough enables faster synthesis and analysis of RNA molecules, opening up new opportunities for medical research and non-invasive diagnostics.
A new study on malignant catarrhal fever (MCF) in cattle reveals the mechanisms of AlHV-1 infection and identifies a crucial viral gene involved in disease development. The research provides a promising basis for developing an effective vaccine against this devastating bovine disease.
Researchers have created nanoparticles that can release drugs in multiple stages, allowing for more precise targeting of specific sites in the body. This technology has the potential to enhance the effectiveness of therapeutics and reduce side effects, paving the way for new treatments and improved patient care.
Researchers at George Mason University's Center for Infectious Disease Research have made a breakthrough in finding a functional cure for HIV. Using an HIV-like virus particle called HIV Rev-dependent lentiviral vector, the team was able to reduce viral reservoirs and boost the immune system to produce antiviral neutralizing antibodies.
Researchers developed a universal influenza vaccine that targets the internal structural proteins of the virus, providing lifetime immunity against evolving viruses. Six out of 11 nonhuman primates inoculated with the vaccine survived exposure to the H5N1 virus, while unvaccinated primates succumbed to the disease.
A new study has found that 90-95% of participants produced strong T-cell responses after exposure to adenoviral vaccines in a lab setting. This unexpected finding may have implications for the effectiveness and safety of future COVID-19 vaccines, as well as other infectious diseases.
A new approach in vaccine research, adaptive platform trials (APTs), offers a flexible adjustment of study design during ongoing clinical trials. This allows for quick adaptation to new developments and enables the recruitment of large numbers of participants across different countries.
Scientists from Hackensack Meridian Health have identified a new potential pathway for developing vaccines against tuberculosis by targeting marginal zone B (MZB) cells, a natural response to TB infection. The discovery suggests that boosting MZB cell activity could provide reliable and durable protection against the disease.
The University of Pennsylvania team has pioneered a novel 'one-pot platform' to produce mRNA delivery particles, accelerating the synthesis process and enabling precise targeting of specific organs. The approach leverages click-like chemistry to create lipid nanoparticles with biodegradable components, enhancing mRNA delivery into cells.
A new urine-based test accurately measures high-risk HPV16 E7 oncoproteins in urine to detect cervical cancer. The test shows promise in making cervical cancer screening more accessible and less invasive.
Researchers at Cornell University have developed a bioelectric device that can detect and classify new coronavirus variants, identifying those most harmful. The device uses a biomembrane on a microchip to recreate the cellular environment for infection, allowing for quick characterization and analysis of variant mechanics.
Researchers at Trinity College Dublin have made a breakthrough in understanding how to improve vaccine responses against the potentially deadly MRSA bacterium. By targeting the immune-suppressive molecule IL-10, they improved the ability of vaccines to protect against infection and reduce bacterial clearance.
Researchers have developed a humanized mouse model with a fully functional human immune system, enabling the study of immunotherapy development, disease modeling, and vaccine development. The new model, called TruHuX, mounts specific antibody responses and can develop full-fledged systemic lupus autoimmunity.
Researchers at Butantan Institute and collaborators developed a more potent version of the BCG vaccine, which protects against tuberculosis by inducing a strong immune response. The new formulation protected animals for a significantly longer period than conventional BCG.
AlphaFold's groundbreaking ability to predict protein structures is set to transform predictive medicine, enabling the development of personalized vaccines and adaptive clinical trials. However, the review also highlights crucial challenges and ethical considerations surrounding AI integration with clinical data.
Researchers at the University of the Witwatersrand have developed a modified BCG vaccine that shows enhanced protection against tuberculosis in mice. The new vaccine candidate could potentially replace or boost existing TB vaccines, providing a novel solution to the global health crisis.
Researchers used single-cell sequencing technology to study immune responses in healthy adult volunteers exposed to SARS-CoV-2. They discovered unique immune responses associated with resisting sustained viral infection and disease, including activation of specialized mucosal immune cells and a reduction in inflammatory white blood cells.
A new study analyzed over 14,600 scientific publications funded by more than $4 billion in NIH grants, revealing key research topics such as clinical trials, vaccine distribution, and virology. The findings suggest that half of the funding went to five states: North Carolina, Washington, New York, California, and Massachusetts.
Prof. Tomer Hertz's research will measure immune responses to polioviruses using a novel antigen array, facilitating rapid analysis in countries where polio has yet to be eradicated. The funding aims to optimize PAM – a polio antigen microarray – for safe and effective measurement of protection from polio infection.
A new commentary urges public health researchers to incorporate questions about partisan identity in demographic data collection, arguing that excluding this information could lead to ineffective policy and health promotion interventions. By including partisanship in more public health surveys, researchers can better track its impact o...
Researchers at La Jolla Institute for Immunology found that people who experienced breakthrough COVID-19 infections develop T cells better equipped to recognize and target SARS-CoV-2. The study also discovered that B cells produce more diverse antibodies targeting common epitopes between the vaccine and variants.
A new Lancet Series estimates that over 750,000 deaths associated with antimicrobial resistance (AMR) could be prevented annually through improved prevention methods. AMR poses significant threats to newborns, elderly individuals, and those with chronic illnesses, causing nearly 5 million deaths globally each year.
Scientists at the University of Nottingham have created a powerful method to analyze RNA structures in unprecedented detail. By combining cryogenic OrbiSIMS with advanced computational modelling and automation, they can now determine RNA structures in a matter of days, significantly advancing the field of RNA structural biology.
The study reviews various immunotherapies for HCC, including ICIs and cellular therapies, highlighting their potential in managing advanced disease and preventing recurrence. Emerging strategies like vaccine development and oncolytic virotherapy are also discussed.
Researchers found that repeat COVID-19 vaccinations elicit cross-reactive neutralizing antibodies capable of targeting multiple SARS-CoV-2 variants and distantly related coronaviruses. The findings suggest periodic re-vaccination may help build a stock of protective antibodies against emerging variants.
The HPV vaccination programme is helping to close health inequalities in cervical cancer, with most cases prevented in more deprived groups. The study found that the vaccine reduced cervical cancer incidence rates by nearly 90% and pre-cancerous conditions by around 95% in women who received routine vaccination at 12-13 years old.
F. William Studier, a senior biophysicist at Brookhaven National Laboratory, has won the 2024 Merkin Prize in Biomedical Technology for his T7 expression technology, enabling large-scale production of RNA and proteins for biomedical research and pharmaceuticals. His work has saved millions of lives with COVID-19 mRNA vaccines.
Researchers developed a synthetic biomarker technology that can differentiate between prior Zika and dengue virus infections. The technology, using epitope surrogates, correctly identified people previously infected with Zika virus 85.3% of the time.
Researchers have identified new cellular targets for a vaccine to treat eczema in children, which may limit the severity of symptoms and reduce antibiotic use. The study uncovered specific immune signatures in children with infected flares of eczema, providing a potential blueprint for future therapies.
A third Covid vaccine dose has been shown to improve defensive antibody responses in some clinically extremely vulnerable patients. The trial found that 90% of patients who received a booster dose developed significant antibodies, but more than half of those with low initial responses saw no improvement.